Influence of Dehydroxymethylepoxyquinomicin on Radiosensitivity of Thyroid Carcinoma TPC-1 Cells

doi:10.1155/2022/5026308

	Influence of Dehydroxymethylepoxyquinomicin on Radiosensitivity of Thyroid Carcinoma TPC-1 Cells
	Liu, Jie 1; Cai, Hu 3; Yi, Heqing 1; Li, Xin 1; Peng, Yunsong 2; Li, Linfa 1
刊名	JOURNAL OF ONCOLOGY
	2022-09-30
卷号	2022
ISSN号	1687-8450
DOI	10.1155/2022/5026308
通讯作者	Li, Linfa(pet-ct001@163.com)
英文摘要	Objective. To investigate the influence of dehydroxymethylepoxyquinomicin (DHMEQ), an NF-kappa B inhibitor, on radiosensitivity of thyroid carcinoma (TC) TPC-1 cells. Methods. The isolation of CDl33 positive cells (CD133(+) TPC-1) and negative cells (CD133(-) TPC-1) from TPC-1 cells used immunomagnetic bead sorting. After verification of the toxicity of DHMEQ to cells by MTT and cell cloning assays, the cells were divided into four groups, of which three groups were intervened by DHMEQ, I-131 radiation, and DHMEQ +I-131 radiation, respectively, while the fourth group was used as a control without treatment. Alterations in cell growth, apoptosis, and cell cycle were observed. Results. DHMEQ had certain toxic effects on TPC-1 cells, with an IC50 of 38.57 mu g/mL (P < 0.05). DHMEQ inhibited CD133(+) and CD133- TPC-1 proliferation and their clonogenesis after irradiation. DHMEQ + radiation contributed to a growth inhibition rate and an apoptosis rate higher than either or them alone (P < 0.05), with a more significant effect on CD133(-) TPC-1 than CD133+ TPC-1 under the same treatment conditions (P < 0.05). Conclusion. DHEMQ can increase the radiosensitivity of TC cells to I-131, inhibit tumor cell growth, and promote apoptosis. However, its effect is less significant on CD133(+) TPC-1 compared with CD133(-) TPC-1, which may be related to the stem cell-like properties of CD133(+) cells. In the future, the application of DHMEQ in TC 131I radiotherapy will effectively improve the clinical effect of patients.
资助项目	Zhejiang medical and health science and technology project ; National Natural Science Foundation of China ; Zhejiang Provincial Medical Health Science and Technology Project ; Zhejiang Provincial Traditional Chinese Medicine Project ; Natural Science Foundation of Zhejiang Province ; [2019KY045] ; [81903982] ; [2018KY296] ; [2016ZB019]
WOS关键词	FACTOR-KAPPA-B ; THERAPEUTIC TARGET ; PROGRESSION ; APOPTOSIS ; INHIBITOR
WOS研究方向	Oncology
语种	英语
出版者	HINDAWI LTD
WOS记录号	WOS:000868325800006
资助机构	Zhejiang medical and health science and technology project ; National Natural Science Foundation of China ; Zhejiang Provincial Medical Health Science and Technology Project ; Zhejiang Provincial Traditional Chinese Medicine Project ; Natural Science Foundation of Zhejiang Province
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/129422]
专题	中国科学院合肥物质科学研究院
通讯作者	Li, Linfa
作者单位	1.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc Chinese, Dept Nucl Med,Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc Chinese, Dept Pharm,Canc Hosp, Hangzhou 310022, Zhejiang, Peoples R China 3.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Inst Basic Med & Canc Chinese, Dept Integrated Tradit Chinese & Western Med,Canc, Hangzhou 310022, Zhejiang, Peoples R China
推荐引用方式 GB/T 7714	Liu, Jie,Cai, Hu,Yi, Heqing,et al. Influence of Dehydroxymethylepoxyquinomicin on Radiosensitivity of Thyroid Carcinoma TPC-1 Cells[J]. JOURNAL OF ONCOLOGY,2022,2022.
APA	Liu, Jie,Cai, Hu,Yi, Heqing,Li, Xin,Peng, Yunsong,&Li, Linfa.(2022).Influence of Dehydroxymethylepoxyquinomicin on Radiosensitivity of Thyroid Carcinoma TPC-1 Cells.JOURNAL OF ONCOLOGY,2022.
MLA	Liu, Jie,et al."Influence of Dehydroxymethylepoxyquinomicin on Radiosensitivity of Thyroid Carcinoma TPC-1 Cells".JOURNAL OF ONCOLOGY 2022(2022).